Literature DB >> 15539504

Establishment of diagnostic cutoff points for levels of serum antibodies to pertussis toxin, filamentous hemagglutinin, and fimbriae in adolescents and adults in the United States.

Andrew L Baughman1, Kristine M Bisgard, Kathryn M Edwards, Dalya Guris, Michael D Decker, Kathy Holland, Bruce D Meade, Freyja Lynn.   

Abstract

Numerous reports have documented that serologic methods are much more sensitive than culture for the diagnosis of pertussis in adolescents and adults. However, a standardized serologic test for pertussis is not routinely available to most clinicians, and the serologic test levels or cutoff points correlated with diseases have not been determined. The goal of the present study was to examine the distribution of immunoglobulin G (IgG) levels against three Bordetella pertussis antigens (pertussis toxin [PT], filamentous hemagglutinin [FHA], and fimbria types 2 and 3 [FIM]) and to determine population-based antibody levels for the purpose of establishing such diagnostic cutoff points. Enzyme-linked immunosorbent assays (ELISAs) were performed with sera from >6,000 U.S. residents aged 6 to 49 years who participated in the Third National Health and Nutrition Examination Survey. Mixture models were developed to identify hypothesized exposure groups and establish diagnostic cutoffs. Quantifiable (>20 ELISA units/ml [EU]) anti-FHA and anti-FIM IgG antibodies were common (65 and 62% of individuals, respectively), but quantifiable anti-PT IgG antibodies were less frequent (16%). Given the distributions of antibody levels, an anti-PT IgG level of > or =94 EU was proposed as the diagnostic cutoff point. Application of this cutoff point to culture-confirmed illness in a prior study investigating cough illness yielded a high diagnostic sensitivity (80%) and specificity (93%). A standardized ELISA for anti-PT IgG with a single serum sample appears to be useful for the identification of recent B. pertussis infection in adolescents and adults with cough illness. The PT cutoff point will be further evaluated in prospective studies of confirmed B. pertussis infection.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15539504      PMCID: PMC524757          DOI: 10.1128/CDLI.11.6.1045-1053.2004

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN: 1071-412X


  52 in total

1.  Serologic response and antibody-titer decay in adults with pertussis.

Authors:  Ulrich Heininger; James D Cherry; Klemens Stehr
Journal:  Clin Infect Dis       Date:  2004-01-29       Impact factor: 9.079

2.  Sample design: Third National Health and Nutrition Examination Survey.

Authors:  T M Ezzati; J T Massey; J Waksberg; A Chu; K R Maurer
Journal:  Vital Health Stat 2       Date:  1992-09

Review 3.  Pertussis and its prevention: a family affair.

Authors:  E A Mortimer
Journal:  J Infect Dis       Date:  1990-03       Impact factor: 5.226

4.  Use of mixture models in determining laboratory criterion for identification of seropositive individuals: application to parvovirus B19 serology.

Authors:  R A Parker; D D Erdman; L J Anderson
Journal:  J Virol Methods       Date:  1990-02       Impact factor: 2.014

5.  Bordetella parapertussis and Bordetella bronchiseptica contain transcriptionally silent pertussis toxin genes.

Authors:  B Aricò; R Rappuoli
Journal:  J Bacteriol       Date:  1987-06       Impact factor: 3.490

6.  Major outbreak of pertussis in northern Alberta, Canada: analysis of discrepant direct fluorescent-antibody and culture results by using polymerase chain reaction methodology.

Authors:  C A Ewanowich; L W Chui; M G Paranchych; M S Peppler; R G Marusyk; W L Albritton
Journal:  J Clin Microbiol       Date:  1993-07       Impact factor: 5.948

7.  The normal range--a common misuse.

Authors:  E A Murphy; H Abbey
Journal:  J Chronic Dis       Date:  1967-02

8.  Pertussis in Massachusetts, 1981-1991: incidence, serologic diagnosis, and vaccine effectiveness.

Authors:  C D Marchant; A M Loughlin; S M Lett; C W Todd; L H Wetterlow; R Bicchieri; S Higham; P Etkind; E Silva; G R Siber
Journal:  J Infect Dis       Date:  1994-06       Impact factor: 5.226

9.  The 1993 epidemic of pertussis in Cincinnati. Resurgence of disease in a highly immunized population of children.

Authors:  C D Christie; M L Marx; C D Marchant; S F Reising
Journal:  N Engl J Med       Date:  1994-07-07       Impact factor: 91.245

10.  Pertussis hospitalizations and mortality in the United States, 1985-1988. Evaluation of the completeness of national reporting.

Authors:  R W Sutter; S L Cochi
Journal:  JAMA       Date:  1992-01-15       Impact factor: 56.272

View more
  44 in total

1.  Seroprevalence of pertussis among Danish patients with cough of unknown etiology.

Authors:  Tine Dalby; Zitta B Harboe; Karen Angeliki Krogfelt
Journal:  Clin Vaccine Immunol       Date:  2010-10-06

2.  Update on pertussis and pertussis immunization.

Authors:  Jung Yun Hong
Journal:  Korean J Pediatr       Date:  2010-05-31

3.  Does tetanus-diphtheria-acellular pertussis vaccination interfere with serodiagnosis of pertussis infection?

Authors:  Lucia C Pawloski; Kathryn B Kirkland; Andrew L Baughman; Monte D Martin; Elizabeth A Talbot; Nancy E Messonnier; Maria Lucia Tondella
Journal:  Clin Vaccine Immunol       Date:  2012-04-25

4.  Utility of composite reference standards and latent class analysis in evaluating the clinical accuracy of diagnostic tests for pertussis.

Authors:  Andrew L Baughman; Kristine M Bisgard; Margaret M Cortese; William W Thompson; Gary N Sanden; Peter M Strebel
Journal:  Clin Vaccine Immunol       Date:  2007-11-07

5.  Characterization of serological responses to pertussis.

Authors:  Mineo Watanabe; Beverly Connelly; Alison A Weiss
Journal:  Clin Vaccine Immunol       Date:  2006-03

6.  Measuring immunoglobulin g antibodies to tetanus toxin, diphtheria toxin, and pertussis toxin with single-antigen enzyme-linked immunosorbent assays and a bead-based multiplex assay.

Authors:  Sabine Reder; Marion Riffelmann; Christian Becker; Carl Heinz Wirsing von König
Journal:  Clin Vaccine Immunol       Date:  2008-03-05

7.  Development and analytical validation of an immunoassay for quantifying serum anti-pertussis toxin antibodies resulting from Bordetella pertussis infection.

Authors:  Sandra L Menzies; Vijay Kadwad; Lucia C Pawloski; Tsai-Lien Lin; Andrew L Baughman; Monte Martin; Maria Lucia C Tondella; Bruce D Meade
Journal:  Clin Vaccine Immunol       Date:  2009-10-28

8.  Brief Report: Seroprevalence of Pertussis Infection in HIV-Infected Adults in the United States.

Authors:  Stephanie B Troy; Alexandria E-B Rossheim; DaShaunda D Hilliard; Tina D Cunningham
Journal:  J Acquir Immune Defic Syndr       Date:  2016-11-01       Impact factor: 3.731

9.  Association between the timing of maternal vaccination and newborns' anti-pertussis toxin antibody levels.

Authors:  Lourdes R A Vaz-de-Lima; Helena Keico Sato; Eder Gatti Fernandes; Ana Paula Sayuri Sato; Lucia C Pawloski; Maria Lucia Tondella; Cyro A de Brito; Expedito J A Luna; Telma Regina M P Carvalhanas; Euclides A de Castilho
Journal:  Vaccine       Date:  2019-05-29       Impact factor: 3.641

10.  Incidence and reproduction numbers of pertussis: estimates from serological and social contact data in five European countries.

Authors:  Mirjam Kretzschmar; Peter F M Teunis; Richard G Pebody
Journal:  PLoS Med       Date:  2010-06-22       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.